Strategic partnership Claret Bioscience recently partnered with New England Biolabs to co-promote a sequencing sample preparation workflow for DNA methylation and fragmentation analysis, signaling openness to channel partnerships and co-selling opportunities with established players.

Early-stage traction As a small, early-stage biotech startup with a focused offering in NGS library prep and DNA assay design, Claret presents a target for pilot programs, beta testing opportunities, and early adopter deals to validate their single-stranded approach.

Tight-focused use cases Product emphasis on liquid biopsies, FFPE, and ancient DNA indicates potential upsell to customers in molecular diagnostics, oncology liquid biopsy labs, pathology labs, and research groups needing specialized fragmentomics and methylation workflows.

Funding and scale Revenue range cited suggests modest but growing commercial activity; opportunities exist for value-based collaborations, sponsored research, and contract development to scale their platform while leveraging partnerships with larger biootherapy and sequencing players.

Talent and collaboration Active recruitment and a multi-disciplinary team signal readiness to collaborate with experienced scientists and bioinformaticians; potential for joint grant proposals, technical advisory roles, and co-development deals with analytics or software partners.